Since the implementation of the Braak neurofibrillary tangle (NFT) staging system to show the distribution of tau deposition in AD [14], neuropathological evaluation has relied on semiquantitative scoring systems measuring the number of tau inclusions observed in neuronal and/or glial cells [15]. This evidence concerns the gene MAPT and Alzheimer disease.